	US 12,263,179 B1
	Lyme disease-associated T cell receptor-related methods
Harlan S. Robins, Seattle, WA (US); Thomas M. Snyder, San Bruno, CA (US); Mark Klinger, Seattle, WA (US); Jonathan M. Carlson, Redmond, WA (US); and Julia Greissl, Redmond, WA (US)
Assigned to Adaptive Biotechnologies Corporation, Seattle, WA (US)
Filed by Adaptive Biotechnologies Corporation, Seattle, WA (US)
Filed on Jul. 31, 2020, as Appl. No. 16/945,701.
Claims priority of provisional application 62/881,596, filed on Aug. 1, 2019.
Int. Cl. A61K 31/65 (2006.01); A61K 9/00 (2006.01); A61K 31/43 (2006.01); A61K 31/431 (2006.01); A61K 31/53 (2006.01); A61P 31/04 (2006.01); G01N 33/569 (2006.01); G16B 40/00 (2019.01); C07K 14/725 (2006.01)

CPC A61K 31/65 (2013.01) [A61K 9/0019 (2013.01); A61K 31/43 (2013.01); A61K 31/431 (2013.01); A61K 31/53 (2013.01); A61P 31/04 (2018.01); G01N 33/56972 (2013.01); G16B 40/00 (2019.02); G01N 2333/7051 (2013.01); G01N 2800/24 (2013.01)]

10 Claims

1. A computer-implemented method for assessing T cell receptor β chain complementary determining region 3 (TCRβ CDR3) sequences, the method comprising:

assessing TCRβ CDR3 sequences determined from a sample comprising T cells obtained from a subject for the presence or absence of one or more TCRβ CDR3 sequences set forth in SEQ ID NOs: 200, 280, 347, 618, 779, 1026, 1046, 1084, 1688, and 1809;

identifying the subject as having Lyme disease based on the assessment when the one or more TCRβ CDR3 sequences are present; and

administering a therapeutically effective amount of a Lyme disease therapy to the subject, wherein the Lyme disease therapy comprises an oral antibiotic therapy, an intravenous antibiotic therapy, or a combination thereof.